Viewing Study NCT06132958


Ignite Creation Date: 2025-12-25 @ 12:06 AM
Ignite Modification Date: 2026-03-09 @ 7:04 AM
Study NCT ID: NCT06132958
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-24
First Post: 2023-11-10
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module